drugset / Trial / NCT06523764

Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment

NCT06523764

Phase 4 Active not recruiting 208 enrolled Xijing Hospital of Digestive Diseases
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of tegoprazan and minocycline dual therapy for Helicobacter pylori initial treatment. It is hypothesized that tegoprazan and minocycline dual therapy is non-inferior to bismuth-containing quadruple therapy.Patients diagnosed with H. pylori infection will be randomly divided into one of the above treatments. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.

Timeline

Start
2024-11-11
Primary completion
2025-08-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 1000 mg Oral
Comparator Bismuth Potassium Citrate Unknown 240 mg Oral
Comparator Clarithromycin Small molecule 500 mg Oral
Comparator Esomeprazole Small molecule 40 mg Oral
Subject Minocycline Small molecule 100 mg Oral
Subject Tegoprazan Other / unclassified 50 mg Oral

Indications